Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHRANE vs SUPRENZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.
Induction and maintenance of general anesthesia
Management of moderate to severe chronic pain,Off-label: Treatment of opioid use disorder (as a maintenance therapy similar to buprenorphine)
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
Adults: 200 mg orally twice daily with meals.
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing for twice-daily dosing.
Primarily hepatic via cytochrome P450 (CYP2E1); minor metabolism to fluoride ions.
Primarily hepatic via CYP3A4 and CYP3A5 to norbuprenorphine (active metabolite); also undergoes glucuronidation.
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
Approximately 60-80% of a dose is excreted renally as unchanged drug, with 20-40% eliminated via biliary/fecal routes.
Approximately 30-40%, primarily to albumin.
Approximately 95-98% bound to plasma proteins, primarily albumin.
Vd: 1.2-2.0 L/kg, indicating extensive distribution into tissues, especially fat.
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume.
By inhalation: 100% as delivered; not administered orally.
Oral bioavailability is approximately 70-80%.
No dose adjustment required for GFR >10 m L/min; use with caution in severe renal impairment (GFR <10 m L/min) due to potential accumulation of inorganic fluoride metabolites.
e GFR <45 m L/min/1.73m²: contraindicated. e GFR ≥45: no adjustment.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment as metabolism may be decreased.
Child-Pugh Class A: no adjustment; Class B: reduce to 200 mg once daily; Class C: contraindicated.
Induction: 2-5% inspired concentration; Maintenance: 1-3% inspired concentration, adjusted to age and response.
Not recommended for patients under 18 years; safety and efficacy not established.
Lower inspired concentrations (0.5-2%) recommended due to increased sensitivity and reduced clearance; titrate to effect.
No specific dose adjustment; monitor renal function and use caution due to increased risk of adverse effects.
None
Risk of respiratory depression, especially in non-opioid-tolerant patients. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of serious injury or death due to accidental exposure in children.
May cause dose-dependent cardiovascular depression,Risk of malignant hyperthermia,Potential for nephrotoxicity due to fluoride release,Hepatotoxicity risk, especially with repeated use,Neurologic effects including seizure activity at high doses
Respiratory depression, particularly in the first 24-72 hours of treatment; caution in patients with pulmonary disease. Risk of QT prolongation. Adrenal insufficiency. Severe hypotension. Risk of misuse, abuse, and addiction. Tolerance and physical dependence.
Known hypersensitivity to enflurane or other halogenated anesthetics,Known or suspected susceptibility to malignant hyperthermia,Severe hepatic impairment,Uncontrolled epilepsy
Hypersensitivity to buprenorphine or any component of the formulation. Severe respiratory insufficiency. Acute or severe bronchial asthma. Gastrointestinal obstruction, including paralytic ileus.
No specific food interactions. Patient must follow preoperative fasting guidelines (nil per os, NPO) as directed by anesthesiologist to reduce risk of aspiration.
No significant food interactions. Grapefruit juice may increase buprenorphine levels; avoid large quantities.
FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal hypoxia from maternal hypotension.
Supr ENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: risk of continued virilization, including phallic enlargement and ambiguous genitalia. Fetal growth restriction may occur.
Excreted in breast milk in low amounts; M/P ratio not established. Consider benefits of breastfeeding vs. risk of infant exposure. Minimal systemic absorption in infant expected.
Testosterone is present in breast milk; M/P ratio not reported. Avoid breastfeeding due to potential for androgenization of the infant. Use only if clearly needed and no safer alternative.
No specific dose adjustments required for pregnancy; however, MAC decreases by approximately 30% during pregnancy due to hormonal changes and increased progesterone. Monitor depth of anesthesia closely.
Not applicable; Supr ENza is contraindicated in pregnancy. No dose adjustments are recommended as use is avoided entirely.
ETHRANE (enflurane) is a potent inhalation anesthetic. Its use is limited due to risk of seizures at high doses and potential for nephrotoxicity from fluoride ion release. Avoid in patients with history of seizures or renal impairment. Rapid induction and recovery; use with caution in hypotensive patients due to myocardial depression. Malignant hyperthermia trigger.
SUPRENZA (buprenorphine/naloxone) sublingual film is used for opioid dependence. Monitor for respiratory depression especially when combined with benzodiazepines or alcohol. The naloxone component is poorly absorbed sublingually but precipitates withdrawal if injected. Administer only after clear signs of withdrawal to avoid precipitated withdrawal. Adjust dose in hepatic impairment as buprenorphine is hepatically metabolized.
You will receive this anesthesia medication only in a hospital setting under expert supervision.,Possible side effects include nausea, vomiting, shivering, and confusion after waking up.,Tell your doctor if you have a history of seizures, kidney problems, or muscle disorders.,Avoid driving or operating machinery for at least 24 hours after anesthesia.,Do not eat or drink for the time specified by your healthcare team before surgery.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Place film under the tongue until fully dissolved; do not chew or swallow.,Avoid alcohol and benzodiazepines as they can cause severe respiratory depression.,Keep out of reach of children; accidental exposure can be fatal.,Do not abruptly stop; withdrawal symptoms may occur.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHRANE vs SUPRENZA, answered by our medical review team.
ETHRANE is a General Anesthetic that works by Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.. SUPRENZA is a Sympathomimetic Anorectic that works by Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHRANE and SUPRENZA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHRANE is: 1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.. The standard adult dose of SUPRENZA is: Adults: 200 mg orally twice daily with meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHRANE and SUPRENZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHRANE is classified as Category C. FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal . SUPRENZA is classified as Category C. SuprENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnorm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.